Inivata Raises $52.6M For Liquid Biopsy Commercialization
Inivata has raised $52.6m to support commercialization of its blood test for non-small cell lung cancer (NSCLC) diagnosis.
You may also be interested in...
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.